2211.HK stock down 79% pre-market Jan 31 2026: top loser with valuation gap
2211.HK stock plunged 79.03% pre-market on 31 Jan 2026 to HKD 1.08, marking it among Hong Kong’s top losers. Volume spiked to 55,949,630 shares versus an average of 1,614,497, signaling forceful selling. Traders should note the intraday range from HKD 0.90 to HKD 5.22 and the large gap from the previous close of HKD 5.15. Below we dissect drivers behind the move, valuation signals, technical indicators and what Meyka AI’s model projects next
2211.HK stock: price action and trading metrics
Universal Health International Group Holding Limited (2211.HK) opened HKD 5.12 and collapsed to HKD 1.08 pre-market on 31 Jan 2026. The day low was HKD 0.90 and the year high is HKD 5.36. Volume surged to 55,949,630, a 34.52x relative volume spike compared with the average of 1,614,497.
This level of volume with a 79.03% decline indicates heavy sell orders and possible block trades or news-driven liquidation. Market cap now sits near HKD 86,515,392 with 80,106,844 shares outstanding.
2211.HK stock: financials and valuation snapshot
Universal Health’s trailing twelve-month EPS is -0.36, yielding a negative P/E near -3.00. Price-to-book is 0.24, with book value per share HKD 3.96. Price-to-sales stands at 0.11, and free cash flow per share is HKD 0.11.
Those ratios show low market pricing versus book value but negative profitability. Current ratio is 1.31 and debt-to-equity is 0.08, indicating modest leverage. Analysts should weigh the cheap PB against persistent negative margins and interest coverage at -97.48.
2211.HK stock: technicals and sector comparison
Technically 2211.HK is oversold. RSI is 17.59, MACD histogram is -0.04, and ADX reads 29.84 suggesting a strong downward trend. Bollinger middle band is HKD 1.75 and lower band is HKD 1.44, both above the pre-market price.
In Hong Kong’s Healthcare sector, average PE is 29.06 and average current ratio is 3.65. Universal Health’s margins and returns lag sector peers, highlighting why the stock trades at a deep discount despite a conservative balance sheet.
Meyka AI rates 2211.HK with a score out of 100 and forecast
Meyka AI rates 2211.HK with a score out of 100: 60.00/100, Grade B — HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals.
Meyka AI’s forecast model projects monthly HKD 1.36, quarterly HKD 2.02, and yearly HKD 3.29. Against the current price HKD 1.08, the model implies a monthly upside of 25.93%, quarterly upside of 87.04%, and yearly upside of 204.28%. Forecasts are model-based projections and not guarantees. Meyka AI provides this as AI-powered market analysis for context.
2211.HK stock: risks, catalysts and news links
Primary risks include continued negative earnings, low interest coverage, and volatile trading that can force further markdowns. The EPS is negative HKD 0.36, and operating profit margin is -3.59%, highlighting profitability risk.
Potential catalysts are: recovery in regional retail drug demand, clearer earnings guidance, or corporate actions that restore confidence. Check the company site for filings and statements: Universal Health website. For consolidated market data and historical quotes see the company profile at FinancialModelingPrep.
2211.HK stock: short-term trading outlook
Short-term traders should expect high volatility and wide intraday ranges. The immediate technical support is near HKD 0.76 (year low HKD 0.76) and resistance sits around the 50-day average HKD 2.14.
Position sizing and stop-loss discipline are key. Given the oversold indicators and extreme volume, a snap recovery is possible, but sustained upside requires restoration of margins or positive news.
Final Thoughts
2211.HK stock is one of Hong Kong’s most notable pre-market losers on 31 Jan 2026, falling to HKD 1.08 on a 79.03% drop and record volume near 55.95 million shares. Valuation metrics show a low PB of 0.24 but negative profitability with EPS -0.36 and interest coverage -97.48, so the market has priced in significant risk. Meyka AI’s model projects a yearly target of HKD 3.29, implying 204.28% upside from today’s level, while shorter horizons show monthly and quarterly targets of HKD 1.36 and HKD 2.02 respectively. These forecasts are model-based and not guarantees. For traders, the combination of heavy selling, negative margins, and thin fundamental improvements suggests a tactical approach. Investors seeking recovery exposure should wait for improving earnings and clearer corporate communication. Short-term traders can consider opportunistic plays sized for high volatility, while longer-term holders must monitor profit margins and cash flow recovery before adding material exposure.
FAQs
Why did 2211.HK stock plunge pre-market on Jan 31 2026?
2211.HK stock plunged on heavy selling and a gap down from HKD 5.15 to HKD 1.08. Volume surged to 55,949,630 shares. The move aligns with weak profitability and negative EPS of HKD -0.36, prompting rapid risk re-pricing.
What is Meyka AI’s rating and forecast for 2211.HK stock?
Meyka AI rates 2211.HK 60.00/100, Grade B — HOLD. The model projects monthly HKD 1.36, quarterly HKD 2.02 and yearly HKD 3.29. Forecasts are model-based projections and not guarantees.
Is 2211.HK stock cheap based on valuation metrics?
Valuation looks cheap on price-to-book at 0.24 and price-to-sales at 0.11. However the company reports negative margins and EPS -0.36. Cheap valuation may reflect real operational risks rather than a simple bargain.
What are key technical levels to watch for 2211.HK stock?
Watch immediate support near the year low HKD 0.76 and resistance near the 50-day average HKD 2.14. RSI 17.59 indicates oversold conditions, but trend strength (ADX 29.84) favors caution.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
